Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03989011
Other study ID # NL68953.091.19
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2019
Est. completion date December 1, 2023

Study information

Verified date April 2024
Source Rijnstate Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Abdominal aortic aneurysm (AAA) is a common vascular disease and associated with risk of rupture, but also with a high cardiovascular (CV) event rate. A key difficulty in AAA is predicting these life-threatening complications, highlighting the need to explore the potential of novel techniques. Both progression of AAA and CV events are strongly linked to vascular health. In 2013, the SMART risk score is developed to calculate the risk of the patients for recurrent vascular events based on clinical characteristics. Recently, a novel, easy to perform, non-invasive test of endothelial function (the carotid artery reactivity (CAR) test), reflecting target organ damage, has recently been introduced. The CAR is a simple, quick (5-min), non-invasive test that uses ultrasound to examine the carotid artery in response to sympathetic stimulation by placing one hand in cold water. This test shows strong agreement with both coronary and aortic responses to sympathetic stimulation and predicted CV events in patients with peripheral arterial disease. The aim of this prospective 2-year follow-up study is to investigate the predictive capacity of the CAR-test in comparison to the SMART risk score for the development of cardiovascular events in patients with an abdominal aortic aneurysm who have not yet reached the treatment threshold. This could aid clinical decision making in the need for (surgical) intervention, but also alter (drug) treatment to reduce risk of cardiovascular events. Secondary objectives are to investigate the predictive capacity of the CAR-test for progression of the abdominal aortic aneurysm, and to evaluate QoL scores in patients under surveillance for AAA. The aim is to provide insight if these scores can help clinical decision making.


Description:

The investigators will include 167 patients under surveillance for AAA who are all currently under the threshold for repair (i.e. AAA diameter 40-50 mm for men and 35-45 mm for women). Participants will be recruited from all collaborating hospitals (Radboudumc, Rijnstate, CWZ) after providing written informed consent. Additionally, AAA-patients under surveillance of general practitioners are eligible (and will be contacted through the hospital-links), since the nature of the tests allow for performing all tests at the general practitioners' office. In this observational, prospective study, a total of 167 patients under surveillance for an AAA, who are currently under threshold for repair (i.e. AAA diameter 40-50 mm for men and 35-44 mm for women), will be included. Baseline patient characteristics will be registered, including traditional risk factors and CV-history. In addition to regular care of measuring AAA diameter progression (in mm/year), the investigators will perform the CAR-test (10-min) and non-invasive arterial stiffness measures (PWA and PWV with the SphygmoCor device (10-min) one time as baseline. Furthermore, the investigators will ask patients to complete a questionnaire about the quality of their life (Appendix 1). A second questionnaire tries to clarify the disease experience of the patients and can be found in Appendix 2. Both questionnaires will be asked to be completed at the start and the end of the study. Subsequently, the investigators will record major adverse cardiovascular events (MACE) according to the International Classification of Disease-10. Registration of MACE will be performed using hospital-records and following international guidelines. Across a 2-year follow-up, by means of regular follow-up appointments, the investigators will examine AAA progression (in mm/year) and the ability of the CAR parameter and arterial stiffness parameters to predict CV-events.


Recruitment information / eligibility

Status Completed
Enrollment 167
Est. completion date December 1, 2023
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Male or female at least 18 years old; - Informed consent form understood and signed and patient agrees to follow- up visits; - Has an abdominal aortic aneurysm (AAA), who is still under surveillance; Exclusion Criteria: - Life expectancy < 2 years; - Psychiatric or other condition that may interfere with the study; - Participating in another clinical study, interfering on outcomes; - Increased risk for coronary spasms (score Rose-questionnaire =2; this questionnaire can be found in Appendix 3); - Presence of Raynaud's phenomenon, chronic pain syndrome at upper extremity(s), presence of an AV fistula or shunt, open wounds to the upper extremity(s), and/or scleroderma associated with placing the hand in ice water; - Recent (<3 months) presence of angina pectoris, myocardial infarction, cerebral infarction, and/or heart failure, or PAD treatment.

Study Design


Intervention

Diagnostic Test:
Carotid Artery Reactivity test (CAR test)
The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
Arterial stiffness
The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters: Peripheral pressure parameters Central and abdominal aneurysm pressure parameters (derived using a transfer function) Cardiac output parameters (SEVR, ED) Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery.

Locations

Country Name City State
Netherlands Rijnstate Hospital Arnhem
Netherlands Canisius Wilhelmina Ziekenhuis Nijmegen Gelderland
Netherlands Radboudumc Nijmegen Gelderland

Sponsors (3)

Lead Sponsor Collaborator
Rijnstate Hospital Canisius-Wilhelmina Hospital, Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Demographic characteristics Age 2 year follow up
Other Demographic characteristics gender 2 year follow up
Other Demographic characteristics height 2 year follow up
Other Demographic characteristics weight 2 year follow up
Other Demographic characteristics ASA class 2 year follow up
Other Demographic characteristics medical history 2 year follow up
Other Demographic characteristics blood pressure 2 year follow up
Other Demographic characteristics heart rate 2 year follow up
Other Demographic characteristics cardiac measurements 2 year follow up
Other Demographic characteristics SVS class 2 year follow up
Other Medication use Anti-platelets 2 year follow up
Other Medication use anti-coagulants 2 year follow up
Other Medication use anti-hypertensives 2 year follow up
Other Medication use statins 2 year follow up
Other Medication use beta-blockers 2 year follow up
Other Medication use sympathicomimetics 2 year follow up
Other Laboratory results Hemoglobin 2 year follow up
Other Laboratory results serum creatinine 2 year follow up
Other Laboratory results cholesterol 2 year follow up
Other Laboratory results eGFR 2 year follow up
Other Laboratory results crp 2 year follow up
Other Anatomic characteristics of AAA AAA sac diameter 2 year follow up
Other Anatomic characteristics of AAA infrarenal aortic neck lumen diameter 2 year follow up
Other Anatomic characteristics of AAA proximal non-aneurysmal aortic neck length 2 year follow up
Other Anatomic characteristics of AAA proximal aortic neck angle 2 year follow up
Other Anatomic characteristics of AAA aneurysm blood lumen diameter 2 year follow up
Other Anatomic characteristics of AAA common iliac artery diameter left 2 year follow up
Other Anatomic characteristics of AAA common iliac artery diameter right 2 year follow up
Other Anatomic characteristics of AAA blood lumen diameter 2 year follow up
Primary Major Adverse Cardiovascular Events (MACE) Incidence of MACE including myocardial infarction, cerebral infarction, heart failure, and peripheral vascular disease 2 year follow-up
Secondary SMART risk score Second Manifestations of ARTerial disease risk score is developed to determine the risk of recurrent vascular events based on clinical characteristics of the patients Baseline
Secondary SphygmoCor parameters Peripheral pressure measurements (PWA) Baseline
Secondary SphygmoCor parameters central pressure measurements (derived using a transfer function, PWA) Baseline
Secondary SphygmoCor parameters abdominal pressure measurements (derived using a transfer function, PWA) Baseline
Secondary SphygmoCor parameters - cardiac output parameter SEVR Baseline
Secondary SphygmoCor parameters - cardiac output parameter ED Baseline
Secondary SphygmoCor parameters PWV Baseline
Secondary CAR-test results Percentage of vasodilation/vasoconstriction to the CAR test at the common carotid artery at baseline Baseline
Secondary CAR-test results magnitude of the blood flow and perfusion response Baseline
Secondary CAR-test results timing of the blood flow and perfusion response Baseline
Secondary CAR-test results blood pressure responses Baseline
Secondary CAR-test results heart rate responses Baseline
Secondary AAA progression AAA diameter progression in mm/year 2 year follow up
Secondary Aorta repair If the patient underwent aorta repair Within 2 year follow-up
Secondary AAA rupture If the AAA ruptured Within 2 year follow up
Secondary Score EQ-5D questionnaire Patient reported outcomes measured by the general health questionnaire At baseline and after 2 years
Secondary Score IPQ-K questionnaire Patient reported outcomes measured by the disease perception questionnaire At baseline and after 2 years
Secondary Clinical success Incidence of serious adverse events 2 year follow up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04227054 - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks N/A
Active, not recruiting NCT03687489 - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System N/A
Active, not recruiting NCT03507413 - Metformin Therapy in Non-diabetic AAA Patients Phase 2/Phase 3
Not yet recruiting NCT05756283 - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair N/A
Not yet recruiting NCT04089241 - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair N/A
Active, not recruiting NCT02604303 - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Terminated NCT01843335 - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair N/A
Completed NCT02224794 - LIFE Study: Least Invasive Fast-Track EVAR
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT02229006 - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms N/A
Terminated NCT01425242 - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension N/A
Completed NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) Phase 2
Completed NCT00746122 - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair N/A
Completed NCT03952780 - Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
Completed NCT00583414 - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients N/A
Recruiting NCT05864560 - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed NCT01683084 - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Phase 4
Active, not recruiting NCT03180996 - Global Fenestrated Anaconda Clinical sTudy
Completed NCT02493296 - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed NCT03320408 - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers